GHK-Cu and BPC-157 are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Same theme, different classes
It is easy to file GHK-Cu and BPC-157 together because both surface in "tissue repair" searches — but that shared heading hides how little the two molecules have in common at the level that matters. One is a three-residue copper complex first isolated from human plasma; the other is a fifteen-residue fragment isolated from gastric juice. Their mechanisms, their target tissues and their regulatory footnotes diverge almost completely. The useful comparison is not "which repairs tissue better" but "which model system is each one actually built for". Below, the two are placed side by side before we take each in turn.
| GHK-Cu | BPC-157 | |
|---|---|---|
| Class / peptide type | Copper-binding tripeptide (Copper Tripeptide-1) | Synthetic pentadecapeptide (Body Protection Compound-157) |
| Structure | Gly-His-Lys + Cu²⁺ · 3 amino acids | 15-amino-acid sequence (Gly…Val) |
| Molecular weight | <700 Da | ~1419 Da |
| Primary mechanism | Matrix gene expression; collagen/elastin/GAG synthesis; antioxidant and DNA-repair gene modulation | VEGFR2 upregulation and angiogenesis; FAK-paxillin and JAK2/STAT3 signalling |
| Main research focus | Skin remodelling, wound healing, dermatology / cosmetic models | Gastrointestinal, tendon / ligament / muscle, vascular, CNS models |
| Notable property | Naturally occurring; copper coordination via histidine + amino terminus | Stable in gastric acid — unusual among peptides |
| Regulatory status | Research reagent; injectable forms on FDA Category 2 compounding list (2023) | Research reagent; FDA Category 2 (2023); prohibited under WADA |
GHK-Cu: the copper tripeptide
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973, and it is among the most extensively characterised peptides in the biochemical literature. Structurally it is tiny — three residues, under 700 Da — with a copper ion coordinated through its histidine and amino terminus. That copper-binding architecture is central to what it does.
Its best-characterised activity is on fibroblasts: in culture, GHK-Cu stimulates synthesis of collagen (types I, III, IV and VII), elastin, proteoglycans, glycosaminoglycans and decorin — the structural matrix components that define skin architecture. Gene-profiling work using the Connectivity Map found it modulates a strikingly broad gene set, including upregulation of DNA-repair and antioxidant enzyme genes and suppression of NFκB signalling. It also behaves as a chemoattractant, drawing immune and endothelial cells toward injury sites. The research centre of gravity is dermatological and wound-model: skin remodelling, extracellular-matrix composition and preclinical wound closure. Researchers sourcing material can buy GHK-Cu UK in research-grade form, and the full mechanistic detail sits on our GHK-Cu knowledgebase profile.
BPC-157: the gastric pentadecapeptide
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a fifteen-amino-acid fragment derived from a protein isolated in human gastric juice, weighing around 1419 Da. It is one of the most studied tissue-repair peptides in preclinical literature, with more than three decades of published work spanning musculoskeletal tissue, the gastrointestinal system, vascular biology and the central nervous system.
Mechanistically it works through a different set of levers to GHK-Cu. Central among them is upregulation of the VEGFR2 receptor, which drives angiogenesis — new blood-vessel formation being a rate-limiting step in repair. It also activates the FAK-paxillin axis and the JAK2/STAT3 pathway, both governing fibroblast migration and matrix synthesis in tendon, ligament and muscle models, and it modulates nitric oxide synthesis while suppressing pro-inflammatory cytokines such as TNF-α. A defining and unusual trait is acid stability: BPC-157 is not readily degraded in gastric conditions, which is why so much of its early work sits in gastrointestinal models. Research-grade BPC-157 research material is available for laboratory use, with the underlying pathway data on our BPC-157 knowledgebase profile.
What the differences mean in a research context
The two compounds are not competitors so much as tools built for different benches. GHK-Cu is a matrix-and-gene-expression peptide: its signal runs through fibroblast synthesis, transcriptomic modulation and antioxidant pathways, and its natural home is skin and wound-model research. BPC-157 is a vascular-and-signalling peptide: its signal runs through VEGFR2-driven angiogenesis and fibroblast-migration pathways, and its natural home is the gut, tendon and musculoskeletal models. Where GHK-Cu remodels the scaffold, BPC-157 tends to be studied for rebuilding the blood supply that repair depends on.
Size and chemistry reinforce the split. GHK-Cu is a sub-700 Da copper complex whose activity is inseparable from its metal coordination; BPC-157 is a larger, all-peptide sequence whose defining physical trait is gastric-acid stability. That means the practical questions differ too — copper handling and matrix readouts on one side, angiogenic and cytoprotective assays on the other. Because the two act through non-overlapping mechanisms, they are sometimes considered together in broader repair-research programmes rather than as substitutes for one another, each covering a different arm of the repair process.
One caveat applies equally to both. Every finding referenced here comes from preclinical models — cell culture and animal studies — and neither compound is an approved medicine. Injectable GHK-Cu was added to the FDA's Category 2 compounding list in 2023, as was BPC-157, which is additionally prohibited under WADA. Both are supplied only as research reagents, and the datasets behind them describe qualitative trends, not human efficacy.
The bottom line
GHK-Cu and BPC-157 share a headline and almost nothing else. GHK-Cu is the compact copper tripeptide for matrix, skin and wound-model research; BPC-157 is the acid-stable gastric pentadecapeptide for angiogenesis, gut and connective-tissue research. Choose by the model system, not the marketing category. For research-grade material, see our dedicated pages to buy GHK-Cu UK and buy BPC-157 UK, each ≥99% purity with a COA.